Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alaedini, A.
Right arrow Articles by Latov, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alaedini, A.
Right arrow Articles by Latov, N.
Neurology 2001;56:855-860
© 2001 American Academy of Neurology
Articles

A surface plasmon resonance biosensor assay for measurement of anti-GM1 antibodies in neuropathy

Armin Alaedini, PhD; and Norman Latov, MD, PhD

From the Department of Neurology, Columbia University, New York, NY.

Address correspondence and reprint requests to Dr. Armin Alaedini, 650 W. 168th Street, BB 3-323, Department of Neurology, Columbia University, New York, NY 10032; e-mail: aa819{at}columbia.edu

OBJECTIVE: To develop a rapid assay for the detection and measurement of anti-GM1 ganglioside antibodies in patients with neuropathy, using a surface plasmon resonance–based biosensor.

BACKGROUND: Elevated levels of anti-GM1 ganglioside antibodies are observed in patients with acute and chronic motor neuropathies. Assays for detecting anti-GM1 antibodies in serum are increasingly being used to help the physician in the evaluation of these patients.

METHODS: Antigens were immobilized by adsorption of GM1 (active) and GM2 (control) gangliosides onto a dextran-based sensor chip which is in contact with a flow cell carrying the sample. Interaction of specific antibodies directed against GM1 with the ganglioside-coated sensor chip caused a change in refractive index at the surface of the chip, which was detected by an optical sensor, using the phenomenon of surface plasmon resonance. Sera from patients and healthy individuals were analyzed by the new assay and results were compared with those from ELISA. Anti-GM1 antibody isotype was identified by using a secondary antibody.

RESULTS: The binding of anti-GM1 antibodies to the immobilized GM1 was observed in real time after reference subtraction of the response from GM2 control. The response was proportional to antibody concentration. The assay exhibited high specificity for sera from patients with multifocal motor neuropathy and Guillain–Barré syndrome with antibodies against GM1.

CONCLUSIONS: The surface plasmon resonance biosensor assay offers a rapid system for directly measuring antibody levels in serum without the use of any labels, while comparing favorably with the ELISA system in sensitivity and specificity.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by AAN Enterprises, Inc.